肿瘤治疗只是在拖延时间：“生存率”毫无意义，患者会在治疗过程中死去，而早期诊断只会让人“早死”。
原始表述
عشان كده في حاجه اسمها تشخيص مبكر عشان تبقى ميت مبكر
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
肿瘤治疗只是在拖延时间：“生存率”毫无意义，患者会在治疗过程中死去，而早期诊断只会让人“早死”。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! لايف مفاجيء (打开来源)
- 发布日期
- 2025年8月5日
- 时间戳
- 0:16:53 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- 涉及人群
Cancer patients
- Elawady 设定的地域限制
none found
来源版本存在差异
انا جاي اعيش 60 سنه اعيش منهم اربع سنين عشان انت ترتاح انت واللي شبهك كيماوي اشعاع لحد ما اموت
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! التراكمي عال و السكر واطيي (打开来源)
- 发布日期
- 2025年10月5日
- 时间戳
- 0:34:56 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
بيحسبوا نجاحهم في الكيماوي بالبقاء حيا
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- حلقه علميه قويه تواجه التضليل العلمي بالحقيقه (打开来源)
- 发布日期
- 2026年4月17日
- 时间戳
- 1:26:32 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Chemotherapy and radiotherapy give only short survival with suffering; cancer patients die during treatment.
2. 哪些内容可证实是正确的？
Survival statistics can be inflated by earlier detection (lead-time bias) and some screening leads to overdiagnosis - a legitimate methodological point; 5-year survival is not the same as cure. Treatment near death often does not help (C-CHM-07). Treatment-related deaths do occur, but they are rare: in the breast-cancer trial overview, deaths without recurrence in the first year were 0.3% vs 0.2% (taxane vs control, women under 70), non-breast-cancer mortality was higher with anthracycline or CMF chemotherapy than with no chemotherapy (RR 1.20 and 1.24), and cardiac mortality was higher with anthracyclines (RR 1.56) (I-CHM-01).
3. 哪些内容是错误或夸大的？
These treatment-related deaths are far outweighed by the benefit: overall mortality was lower with chemotherapy than without (RR 0.84) (I-CHM-01), and radiotherapy after breast-conserving surgery reduced 15-year all-cause mortality by 3.0 percentage points (0.6-5.4) (I-CHM-02). Many treated patients are cured or live long: childhood ALL 5-year survival 90.4% (I-CHM-05); testicular cancer 10-year relative survival 95% (A-CHM-14); 15-year late mortality among 5-year childhood survivors fell to 6.0% (A-CHM-11); 52% 5-year survival in advanced melanoma with immunotherapy (I-CHM-08); US cancer mortality decline averted over 4 million deaths since 1991, partly through improved treatment (I-CHM-12).
4. 哪些内容仍不明确？
Survival and cure rates differ by cancer type, stage and country; adult Egyptian survival data were not reviewed. The size of lead-time and overdiagnosis effects varies by cancer and screening programme.
5. 哪些研究支持该说法？
Only for the narrow methodological point: from 1950 to 1995, changes in 5-year survival tracked changes in diagnosis (r=+0.49 with incidence) but not changes in mortality (r=0.00) (I-CHM-106); screening can cause overdiagnosis (NLST incidence ratio 1.13; I-CHM-107). Some new drugs add only months (I-CHM-124). None of this supports 'early diagnosis makes you die early'.
6. 哪些研究与该说法相矛盾？
I-CHM-01, I-CHM-02, I-CHM-05, I-CHM-08, I-CHM-12, A-CHM-11, A-CHM-14; I-CHM-107 (low-dose CT screening reduced lung-cancer mortality by 20.0% and all-cause mortality by 6.7% in a randomised trial); I-CHM-103 (chemotherapy raised 1-year survival in advanced lung cancer from 20% to 29%); I-CHM-125 (Egypt: 72.1% 5-year survival in children treated for cancer).
7. 对德国和欧洲而言情况如何？
Same.
8. 关于埃及的已知情况是什么？
At Children's Cancer Hospital Egypt, 5-year survival of 14,808 children treated for cancer was 72.1% and rose over 2007-2017, although it remained about 9-11 points below England and the USA (I-CHM-125).
9. 合理的实际结论是什么？
请向肿瘤科医生询问针对具体癌症类型和分期的绝对生存概率和治愈概率。
评估详情
- 证据确定性的依据
Long-term cure and survival data from randomised trials and registries.
- 来源质量
Machine transcripts.
- 地区可推广性
High.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: Does oncology only 'buy time', are survival statistics meaningless, and does early diagnosis only make people 'die early'?
研究问题详解 (PICO)
- 人群
- People with or at risk of cancer
- 干预或暴露
- Early detection and modern cancer treatment
- 对照
- Later detection; no treatment
- 地域范围
- universal; Egyptian data included
- 结局指标
- Cancer mortality
- All-cause mortality
- Cure rates
- Validity of survival statistics
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Why rising cancer survival rates can mislead
Rising 5-year survival over time tracked rising diagnosis, not falling deaths.
- 实际结果
- r=0.00 with mortality change; r=+0.49 with incidence change
- 方法学质量
- moderate (ecological, 20 tumour types)
- 相关性
- indirect: supports caution about survival trends only
- 局限
- Old data; not about treatment effects
Many new cancer drugs approved without proof of longer or better life
Many new cancer drugs add only months or have unproven benefit.
- 实际结果
- OS benefit at approval in 35%; median 2.7 months
- 方法学质量
- moderate
- 相关性
- indirect
- 局限
- New drugs only
哪些证据不支持该说法？
Lung CT screening trial (NLST)
National Lung Screening Trial Research Team; Aberle DR et al.. N Engl J Med 2011 · PMID 21714641 · DOI 10.1056/NEJMoa1102873 随机对照试验已核查摘要新增Lung-cancer screening RCT: earlier detection plus treatment reduced lung-cancer and all-cause mortality.
- 实际结果
- Lung-cancer mortality -20.0% (6.8-26.7); all-cause -6.7%
- 方法学质量
- high (large RCT, mortality endpoint)
- 相关性
- direct refutation of 'die early'
- 局限
- Overdiagnosis and false positives
Childhood cancer survival in Egypt
In Egypt, 72% of children treated for cancer were alive 5 years later, rising over time.
- 实际结果
- 5-y OS 72.1%; 69.6% -> 74.2%
- 方法学质量
- moderate (very large hospital cohort)
- 相关性
- direct regional evidence
- 局限
- No untreated comparator
About 9 in 10 children with leukaemia now survive
Childhood ALL 5-year survival rose to about 90% with improved treatment.
- 实际结果
- 83.7% -> 90.4%
- 方法学质量
- high (cooperative-group cohort)
- 相关性
- direct
- 局限
- US data
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Modern cancer treatment cures many patients (e.g. most children, testicular cancer) and prolongs life in others; early detection in proven programmes lowers mortality. A legitimate kernel: survival-rate trends can be inflated by lead-time and overdiagnosis, and some new drugs add little.
为什么有些研究权重更大
Mortality-endpoint RCTs avoid lead-time bias and weigh most; ecological and regulatory analyses support only the methodological caveat.
因果关系是否已确立？ 是，已确立 RCTs with mortality endpoints.
仍存在的不确定性
Degree of overdiagnosis in specific screening programmes.
合理的结论
False as stated, with a correct methodological kernel.
为什么研究结果看起来互相矛盾？
Welch 2000 (survival trends misleading) and NLST (mortality reduced) agree methodologically: survival trends can mislead, which is why mortality in randomised trials is used; on that metric early detection plus treatment saves lives.
这是否取决于国家？
- 一般生物学效应
- Universal methodology and clinical evidence.
- 饮食习惯
- Not relevant.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- Egyptian childhood cancer survival 72.1% (I-CHM-125); adult Egyptian survival data not reviewed.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Recompute rate ratio; CI shape – 247/309 = 0.799 (reported 20.0% reduction); reported CI asymmetric on log scale, consistent with interim-monitoring adjustment 已重新计算
- Interpretation – r=0.00 (mortality) vs +0.49 (incidence): supports lead-time/overdiagnosis caveat, not futility 已重新计算
- Absolute trend – +4.6 points 5-y OS between periods 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Mortality with early detection and treatment
- 起始等级
- 高（随机试验）
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · 原始文献
Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer. - NCI: Chemotherapy to Treat Cancer (2026 (fetched 2026-10-26)) · 原始文献
Chemotherapy can be used to cure cancer, lessen the chance it will return, or stop or slow its growth, and to ease symptoms; it also harms fast-growing healthy cells, causing side effects.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:"5-year survival rates" AND TITLE:"evidence of success against cancer" | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (TITLE:"lead-time bias" OR TITLE:"overdiagnosis") AND TITLE:"survival" AND (TITLE:"screening") AND PUB_YEAR:[2000 TO 2026] | 支持性证据 | 5 | |
| Europe PMC | 2026年10月26日 | TITLE:"contribution of cytotoxic chemotherapy to 5-year survival" | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | TITLE:"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency" | 支持性证据 | 2 | |
| Europe PMC | 2026年10月26日 | TITLE:"Reduced lung-cancer mortality with low-dose computed tomographic screening" | 反对性证据 | 1 | |
| Europe PMC | 2026年10月26日 | TITLE:"Reduced Lung-Cancer Mortality with Volume CT Screening" | 反对性证据 | 2 | |
| Europe PMC | 2026年10月26日 | (TITLE:"survival") AND (TITLE:"breast cancer" OR TITLE:"childhood cancer" OR TITLE:"leukemia") AND TITLE:"Egypt" AND PUB_YEAR:[2015 TO 2026] | 反对性证据 | 4 | |
| Europe PMC | 2026年10月26日 | TITLE:"chemotherapy" AND TITLE:"supportive care" AND TITLE:"non-small-cell lung cancer" AND (TITLE:"meta-analysis" OR TITLE:"individual patient") | 反对性证据 | 3 |
待解决的问题
Adult cancer survival in Egypt.
核查深度如何？
13 项相关研究：4 项核查了全文（其中 4 项进行了结构化偏倚风险评估），9 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (高)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (高)
The legitimate kernel (lead-time and overdiagnosis) is now sourced (I-CHM-106) and acknowledged; mortality-endpoint RCTs and Egyptian survival data confirm the verdict.
新来源: I-CHM-106 I-CHM-107 I-CHM-103 I-CHM-125 I-CHM-123 I-CHM-124
通俗解释
Diaa 医生说，癌症治疗只是计算人们能活多久，而早期诊断只会让人“早死”。生存统计数据确实需要谨慎解读，也确实有少数患者死于治疗的副作用。但总体而言，在随机对照试验中，接受治疗的患者比未接受治疗的患者死亡更少。许多患者能被治愈：每10名白血病患儿中约有9名、每100名睾丸癌男性患者中约有95名能够长期存活。几十年来，癌症死亡率一直在下降，部分原因是治疗水平的提高。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (10)
-
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究In 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Overall mortality reduced
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare chemotherapy regimens and no chemotherapy.
- 研究是如何开展的？
IPD meta-analysis of RCTs.
- 研究了多少人、动物或样本？
~100,000 women.
- 实际发现了什么？
~1/3 lower breast-cancer mortality.
- 观察到的效应有多大？
RR 0.64-0.78 vs none.
- 研究结果对日常生活意味着什么？
For many women, chemotherapy substantially raises the chance of survival.
- 该研究有哪些局限？
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- 它对 Elawady 的具体说法说明了什么？
Contradicts claims that chemotherapy is useless.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Individual benefit without risk assessment.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究Recurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure radiotherapy benefit.
- 研究是如何开展的？
IPD meta-analysis.
- 研究了多少人、动物或样本？
10,801 women.
- 实际发现了什么？
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- 观察到的效应有多大？
-15.7% recurrence; -3.8% death.
- 研究结果对日常生活意味着什么？
Radiotherapy markedly lowers the chance the cancer returns.
- 该研究有哪些局限？
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- 它对 Elawady 的具体说法说明了什么？
Benefit side.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Individual benefit size without risk factors.
-
About 9 in 10 children with leukaemia now survive
Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018队列研究独立交叉核查已核查摘要★ 关键研究5-year survival in childhood ALL rose to 90.4% by 2000-2005.
90% 5-year survival
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Track ALL survival.
- 研究是如何开展的？
Trial cohort analysis.
- 研究了多少人、动物或样本？
21,626.
- 实际发现了什么？
83.7% -> 90.4%.
- 观察到的效应有多大？
+6.7 points.
- 研究结果对日常生活意味着什么？
Childhood leukaemia is usually curable with treatment.
- 该研究有哪些局限？
Trial patients.
- 它对 Elawady 的具体说法说明了什么？
Benefit side.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Survival outside trials.
-
Immunotherapy lets half of patients with advanced melanoma live at least five years
Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836随机对照试验独立交叉核查已核查摘要5-year survival 52% with combined immunotherapy vs 26% with the older drug.
Long survival in metastatic disease
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Report 5-year survival.
- 研究是如何开展的？
RCT.
- 研究了多少人、动物或样本？
Advanced melanoma.
- 实际发现了什么？
52% 5-year OS.
- 观察到的效应有多大？
HR 0.52.
- 研究结果对日常生活意味着什么？
The immune system can fight cancer when helped.
- 该研究有哪些局限？
Industry funding.
- 它对 Elawady 的具体说法说明了什么？
Contradicts immune claim.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Effect in other cancers.
-
Cancer death rates in the USA keep falling
Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820其他独立交叉核查已核查摘要More than 4 million cancer deaths averted since 1991 thanks to less smoking, earlier detection and better treatment.
Mortality declining
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Report cancer statistics.
- 研究是如何开展的？
Registry data.
- 研究了多少人、动物或样本？
US population.
- 实际发现了什么？
Declining mortality.
- 观察到的效应有多大？
>4 million deaths averted.
- 研究结果对日常生活意味着什么？
Prevention and treatment both work.
- 该研究有哪些局限？
Descriptive.
- 它对 Elawady 的具体说法说明了什么？
Benefit context.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Share due to treatment alone.
-
Late deaths among childhood-cancer survivors have fallen as treatment became gentler
Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究15-year death rate after surviving 5 years dropped from 12.4% to 6.0% between the 1970s and 1990s.
Most 5-year survivors are alive decades later
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Track late mortality across eras.
- 研究是如何开展的？
Cohort, 34,033 survivors.
- 研究了多少人、动物或样本？
34,033.
- 实际发现了什么？
41% of late deaths health-related; mortality halved over time.
- 观察到的效应有多大？
12.4% -> 6.0%.
- 研究结果对日常生活意味着什么？
Late effects are real and being reduced.
- 该研究有哪些局限？
Observational era comparison; cannot measure improvements in medical care; treatment data imputed for 29%; shorter follow-up for the 1990s.
- 它对 Elawady 的具体说法说明了什么？
Supports burden and shows progress.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
That treatment should be avoided.
-
Testicular cancer survivors face late effects but almost all survive
Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832叙述性综述被 Tayebat 档案网站引用全文，含结构化偏倚风险评估10-year relative survival is 95%; heart disease and second cancers are the main serious late effects.
Curable cancer with cisplatin
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review late effects.
- 研究是如何开展的？
Narrative review.
- 实际发现了什么？
Multiple late effects.
- 研究结果对日常生活意味着什么？
Long-term check-ups and healthy lifestyle.
- 该研究有哪些局限？
Narrative review without systematic search or quality appraisal; much evidence from older treatment eras.
- 它对 Elawady 的具体说法说明了什么？
Mixed.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Quantitative risks.
-
Lung CT screening trial (NLST)
National Lung Screening Trial Research Team; Aberle DR et al.. N Engl J Med 2011 · PMID 21714641 · DOI 10.1056/NEJMoa1102873随机对照试验独立交叉核查已核查摘要★ 关键研究Screening heavy smokers with low-dose CT cut lung-cancer deaths by 20% and deaths from any cause by 6.7%.
Early detection plus treatment lowered lung-cancer and all-cause mortality in an RCT.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether early detection saves lives
- 研究是如何开展的？
Randomised trial
- 研究了多少人、动物或样本？
53,454 high-risk adults
- 实际发现了什么？
Fewer lung-cancer deaths with CT screening
- 观察到的效应有多大？
247 vs 309 deaths per 100,000 person-years
- 研究结果对日常生活意味着什么？
Finding cancer early and treating it can prevent deaths
- 该研究有哪些局限？
Many false alarms; some overdiagnosis
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'early diagnosis makes you die early'
- 研究结果是否适用于德国和欧洲？
Moderate (European trial found similar results)
- 从该研究中明确不能得出什么结论？
Does not apply to low-risk people
-
Chemotherapy vs supportive care alone in advanced lung cancer
NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162Meta分析独立交叉核查已核查摘要★ 关键研究Chemotherapy raised 1-year survival from 20% to 29%.
Even in incurable cancer, treatment buys measurable time, which the claim dismisses.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure survival benefit of chemotherapy in advanced lung cancer
- 研究是如何开展的？
IPD meta-analysis of randomised trials
- 研究了多少人、动物或样本？
2714 patients in 16 trials
- 实际发现了什么？
23% lower risk of death
- 观察到的效应有多大？
HR 0.77; 1-year survival 20% -> 29%
- 研究结果对日常生活意味着什么？
About 1 in 11 treated patients is alive at 1 year because of chemotherapy
- 该研究有哪些局限？
Older drugs; modest absolute gain
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'oncology only buys time' as meaningless and 'chemo often does not help' in fit patients
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Does not show benefit for frail patients in their last weeks
-
Childhood cancer survival in Egypt
Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321队列研究独立交叉核查已核查摘要★ 关键研究At Egypt's main children's cancer hospital, 72% of children were alive 5 years after diagnosis, and survival improved over time.
Egyptian survival figures and rising trends contradict 'oncology only buys time'.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure Egyptian childhood cancer survival
- 研究是如何开展的？
Hospital cohort
- 研究了多少人、动物或样本？
14,808 children
- 实际发现了什么？
Survival rising
- 观察到的效应有多大？
5-y OS 72.1%; 69.6% -> 74.2%
- 研究结果对日常生活意味着什么？
Treatment cures most children in Egypt too
- 该研究有哪些局限？
Single hospital; no untreated group
- 它对 Elawady 的具体说法说明了什么？
Contradicts the futility claim
- 研究结果是否适用于德国和欧洲？
High (Egyptian data)
- 从该研究中明确不能得出什么结论？
Cannot isolate the effect of each treatment
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (3)
-
Why rising cancer survival rates can mislead
Welch HG et al.. JAMA 2000 · PMID 10865276 · DOI 10.1001/jama.283.22.2975生态学研究独立交叉核查已核查摘要★ 关键研究Survival gains over time matched rising diagnosis rates, not falling death rates.
Supports the narrow point that rising survival rates can mislead (lead-time, overdiagnosis); does not support 'early diagnosis makes you die early' or 'treatment only buys time'.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Check whether survival trends reflect real progress
- 研究是如何开展的？
Analysis of US cancer statistics 1950-1995
- 研究了多少人、动物或样本？
20 tumour types
- 实际发现了什么？
Survival changes tracked diagnosis, not deaths
- 观察到的效应有多大？
r=0.00 with mortality; r=+0.49 with incidence
- 研究结果对日常生活意味着什么？
Earlier diagnosis can make survival look longer without people living longer
- 该研究有哪些局限？
Ecological, old data
- 它对 Elawady 的具体说法说明了什么？
Partly supports scepticism about survival statistics; does not show early diagnosis shortens life
- 研究结果是否适用于德国和欧洲？
Moderate
- 从该研究中明确不能得出什么结论？
Cannot judge any specific treatment
-
How much does chemotherapy add to cancer survival overall?
Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007其他独立交叉核查已核查摘要★ 关键研究Across all adult cancer patients, the authors estimated that about 2% are alive at 5 years because of chemotherapy alone.
Often cited to argue oncology is futile; the metric does not measure benefit in treated patients.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate population-level contribution of chemotherapy
- 研究是如何开展的？
Modelling from trials and registries
- 研究了多少人、动物或样本？
22 cancer types
- 实际发现了什么？
About 2.3% of all patients
- 观察到的效应有多大？
2.1-2.3%
- 研究结果对日常生活意味着什么？
Chemotherapy is not the main reason most people survive cancer (surgery and early detection are)
- 该研究有哪些局限？
Denominator includes patients who never needed chemotherapy
- 它对 Elawady 的具体说法说明了什么？
Gives partial support to scepticism, but not to refusing indicated treatment
- 研究结果是否适用于德国和欧洲？
Low
- 从该研究中明确不能得出什么结论？
Cannot show chemotherapy is useless for a given patient
-
Many new cancer drugs approved without proof of longer or better life
Davis C et al.. BMJ 2017 · PMID 28978555 · DOI 10.1136/bmj.j4530其他独立交叉核查已核查摘要Of 68 new cancer-drug approvals in Europe, only about half showed a survival or quality-of-life benefit after 5 years.
Supports that some treatments only add months; does not support 'survival rates are meaningless'.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Check evidence behind new cancer drugs
- 研究是如何开展的？
Cohort of EMA approvals
- 研究了多少人、动物或样本？
68 indications 2009-13
- 实际发现了什么？
Many approvals with uncertain benefit
- 观察到的效应有多大？
35% had OS benefit at approval
- 研究结果对日常生活意味着什么？
Ask what a new drug adds; proven standard treatments are different
- 该研究有哪些局限？
New drugs only
- 它对 Elawady 的具体说法说明了什么？
Partly supports scepticism
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Does not apply to established curative chemotherapy or radiotherapy
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Same.
埃及
At Children's Cancer Hospital Egypt, 5-year survival of 14,808 children treated for cancer was 72.1% and rose over 2007-2017, although it remained about 9-11 points below England and the USA (I-CHM-125).
在我的国家适用什么？
一般科学评估
错误 该说法错误：以死亡率（诊断提前无法使其失真）为指标的随机对照试验表明，早期发现和治疗能挽救生命，许多患者能被治愈；只有“生存率的变化趋势可能因诊断提前和过度诊断而被夸大”这一点是正确的。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
- Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.. Larkin J et al.. N Engl J Med 2019 · PMID 31562797 · DOI 10.1056/NEJMoa1910836
- Cancer statistics, 2024.. Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820
- Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.. Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795
- Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.. Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
- Reduced lung-cancer mortality with low-dose computed tomographic screening.. National Lung Screening Trial Research Team; Aberle DR et al.. N Engl J Med 2011 · PMID 21714641 · DOI 10.1056/NEJMoa1102873
- Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.. NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162
- Temporal trends in childhood cancer survival in Egypt, 2007 to 2017: A large retrospective study of 14 808 children with cancer from the Children's Cancer Hospital Egypt.. Soliman RM et al.. Int J Cancer 2021 · PMID 32997796 · DOI 10.1002/ijc.33321
- Are increasing 5-year survival rates evidence of success against cancer?. Welch HG et al.. JAMA 2000 · PMID 10865276 · DOI 10.1001/jama.283.22.2975
- The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.. Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.. Davis C et al.. BMJ 2017 · PMID 28978555 · DOI 10.1136/bmj.j4530